Senior insider sale
CHIEF FINANCIAL OFFICER at ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$768.2K
18.05K shares
What this filing means
HOHL BENJAMIN plans to sell 18.05K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $768.2K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 6/17/2026ACC: 0001974158-26-000074
Officer· CHIEF FINANCIAL OFFICER
Since Feb 2026
18.05K
Shares to sell
$768.2K
Approx. market value
18.05K
Acquired (3 months)
1
Planned
Securities Acquired — Last 3 Months3
Previously Exercised Stock Option
N/A
3/4/2025
7.96KPreviously Exercised Stock Option
N/A
12/13/2024
3KStock Option Exercise
N/A
8/9/2022
7.09KTotal acquired18.05K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
3/4/2025 | Previously Exercised Stock Option N/A | 7.96K | — |
12/13/2024 | Previously Exercised Stock Option N/A | 3K | — |
8/9/2022 | Stock Option Exercise N/A | 7.09K | — |
| Total | 18.05K | ||
Planned & Completed Dispositions1
NasdaqPlanned
Units to sell
18.05K
Market value
$768.2K
6/17/2026
Total
Units
18.05K
Value
$768.2K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
6/17/2026 | 18.05K | $768.2K | Nasdaq | Planned |
| Total | 18.05K | $768.2K | ||